Retro Biosciences Stock
| Valuation | $1.8B1 |
| Valuation Date | May 22, 2026 |
| Implied Valuation | $1.84B |
| Last Price | $15.31 |
| 52-Week High | $18.80 |
| 52-Week Low | $10.87 |
| YTD Return | +7.06% |
| 1-Year Return | +28.87% |
| 3-Year Return | n/a |
| Total Funding | $1.18B |
| Latest Round Amount | n/a |
| Latest Round | Series B |
| Funding Rounds | 3 |
| IPO Status | Unknown |
| Expected IPO Date | n/a |
| Revenue | n/a |
| Revenue Type | n/a |
| P/S Ratio | n/a |
About Retro Biosciences
Retro Biosciences is a biotechnology company developing therapies that target the cellular drivers of aging, with the goal of adding ten years to healthy human lifespan. Its programs include autophagy drugs, cellular reprogramming and cell-replacement therapies. The lead candidate RTR242 is an oral pill designed to restart autophagy and is in a Phase I trial. Retro Biosciences makes money by developing these prescription medicines for commercialization.
Invest in Retro Biosciences
Retro Biosciences is a private company, so you can't purchase it with a regular brokerage account. However, its shares are available on Clarity (formerly Hiive).
Clarity is a secondary marketplace where accredited investors can buy and sell shares of private, pre-IPO companies. Invest in the world's most exciting startups before they go public.
Invest on ClarityStock Analysis may be compensated for user sign-ups through Clarity links. Clarity is not affiliated with Stock Analysis. Securities offered by Clarity Capital Limited, member of FINRA/SIPC.
Related Companies
News
Sam Altman's longevity company is testing an extra-strength Alzheimer's drug in a new clinical trial
Retro Biosciences is expanding its Australia Phase I trial of RTR242 from 76 to 108 healthy volunteers to test higher doses after the CEO said the study has shown no major safety signals. The oral aut...
Longevity startup Retro Biosciences says latest fundraise values it at $1.8 billion
Retro Biosciences announced the initial close of its next financing round at a $1.8 billion valuation, led by 4P Capital, as it advances its first clinical program RTR242.
Retro Biosciences: Next Phase
Retro Biosciences announced the initial close of its next financing round at a $1.8 billion pre-money valuation, led by 4P Capital. The company did not disclose the amount raised.
Retro Bio commences first-in-human trial
Retro Biosciences dosed the first participant in a Phase I trial of RTR242, an autophagy-enhancing small molecule, in healthy volunteers in Adelaide, Australia. The study also includes exploratory bio...
Aging startup backed by Sam Altman chases $5 billion valuation
STAT reported that Retro Biosciences was chasing a $5 billion valuation in a large fundraising process despite having no clinical data yet.
Accelerating life sciences research
OpenAI and Retro Biosciences said a custom protein-engineering model, GPT-4b micro, designed Yamanaka-factor variants that increased stem-cell reprogramming markers more than 50-fold in vitro. The wor...
Sam Altman-backed Retro Biosciences to raise $1bn for project to extend human life
The Financial Times reported Retro Biosciences was raising a $1 billion round with Sam Altman participating, after he provided the company's $180 million seed.
Longevity Startup Retro Biosciences Is Sam Altman’s Shot at Life Extension
Bloomberg profiled Retro Biosciences' Redwood City lab, built from shipping containers, and its programs in plasma-inspired therapeutics, autophagy and cellular reprogramming. The company was then ope...
Sam Altman invested $180 million into a company trying to delay death
MIT Technology Review revealed that OpenAI CEO Sam Altman provided Retro Biosciences' entire $180 million seed round. CEO Joe Betts-LaCroix had kept the backer confidential at launch.
Mysterious Retro Biosciences Launches to Increase Healthy Human Lifespan by 10 Years
Retro Biosciences came out of stealth with $180 million in funding and three programs in cellular reprogramming, autophagy and plasma-inspired therapeutics. Co-founders are Joe Betts-LaCroix, Sheng Di...